|
1.Xiang Q, Pang X, Liu Z, Yang G, Tao W, Pei Q, Cui Y*. Progress in the development of antiplatelet agents:
Focus on the targeted molecular pathway from bench to clinic[J]. Pharmacol Ther, 2019, 203:107393. IF: 10.557.
2.Liu Z, Xie Q, Zhang H, Mu G, Zhou S, Wang Z, Jiang J, Xiang Q, Cui Y*. Target Drug-Calibrated Anti-Xa Activity Assays
and Expected Peak-Trough Levels in an Asian Population: A Multicenter Study. Am J Cardiovasc Drugs. 2021, 21(6):669-679. IF:3.571
3.Pang X#, Liu H#, He X, Ji T, Zhu Y*, Cui Y*. Potential Anionic Substances Binding to Platelet Factor 4 in Vaccine-Induced
Thrombotic Thrombocytopenia of ChAdOx1-S Vaccine for SARS-CoV-2[J]. Front Immunol. 2021, 12: 782335. IF: 7.561.
4.CuiY, ZhaoX, QiL, LiX, HuangZ, YangG, QianL, DengH, LiH, HuoY*.A Potential Long-Acting LDL-Cholesterol–Lowering PCSK9 Monoclonal Antibody:
Randomized, Placebo-Controlled Phase 1 Studies. JACC: Asia. 2021, 1(3):411-415.
5.Wang Z, Zhao X, He P, Chen S, Jiang J, Harada A, Brooks S, Cui Y*. Idarucizumab Reverses Dabigatran Anticoagulant Activity in Healthy Chinese
Volunteers: A Pharmacokinetics, Pharmacodynamics, and Safety Study[J]. Adv Ther. 2020, 37(9): 3916-28. IF: 3.842.
6.Zhou S, Wang Z, Liu Z, Mu G, Xie Q, Wang Z, Xiang Q*, Gong Y*, Cui Y*. Candidate Gene of NOS3, MMP3, AGT,
and AGT1R and Pathway Analyses for Platelet Reactivity and Clinical Outcomes of Repeat Revascularization After First PCI in Chinese Patients[J].
Cardiovasc Drugs Ther. 2021. Online ahead of print. IF: 3.727.
7.Su X, Pang X, Zeng X, Gao Y, Cui Y*, Wang H*. Analysis of Suspension of Clinical Trials for Drug Registration in China[J].
Front Pharmacol. 2020, 11: 598574. IF: 5.811.
8.Ma L, Xiang Q, Zhao N, Hu C, Fang M, Tan Y, Chen S, Wang Z, Liu P, Sun K, Li Y, Wu F, Tian H, Fang M, Zhao X, Wang G*, Cui Y*.
Effects of CYP2D6, CYP3A5, and ABCB1 gene polymorphisms on the pharmacokinetics of two risperidone long-acting injection microsphere
formulations[J]. Prog Neuropsychopharmacol Biol Psychiatry. 2021, 109: 110241. IF: 5.067.
9.Zhao N, Jia B, Zhao H, Xu J, Sheng X, Luo L, Huang Z, Wang X, Ren Q, Zhang Y, Zhao X, Cui Y. A First-in-Human Trial of GLS4,
a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir
in Healthy Adult Volunteers[J]. Antimicrob Agents Chemother, 2019, 64(1):e01686-19. IF: 4.904.
10.Xu J, Zhao J, Dong Y, Zhao X, Chen R, Shi Y, Tao J, Cao F, Cui Y*, Bai W*. Photodetection and Safety of 5-Aminolevulinic Acid-Induced Porphyrin
in Patients With Cervical Intraepithelial Neoplasia[J]. Lasers Surg Med. 2021, 53(5): 654-63. IF: 4.025.
11.Zhang E#, Wu Y#, Chen C, Wei R, Zhang J, Xie H, Wei C, Ma L, Dong X, Li R, Zhou Y, Cui Y*, Wu Y*. Effect of different initial rituximab regimens
on B cell depletion in children with autoimmune neurological diseases[J]. Mult Scler Relat Disord. 2022, 59: 103510. IF: 4.339.
12.Zhang YH, Cui YM*. Gut microbiome metabolism drives the resolution of patients with COVID-19[J]. Gastroenterology.
2021. Online ahead of print. IF: 22.682.
13.Xu L, Liu Y, Fan Z, Jiang Z, Liu Y, Ling R, Zhang J, Yu Z, Jin F, Wang C, Cui S, Wang S, Mao D, Han B, Wang T, Zhang G, Wang T,
Guo B, Yu L, Xu Y, Fu F, Liu Z, Wang S, Luo K, Xiang Q, Zhang Z, Liu Q, Zhou B, Liu Z, Ma C, Tong W, Mao J, Duan X*, Cui Y*.
Assessment of CPS + EG, Neo-Bioscore and Modified Neo-Bioscore in Breast Cancer Patients Treated With Preoperative Systemic Therapy:
A Multicenter Cohort Study[J]. Front Oncol. 2021, 11: 606477. IF: 6.244.
14.Pang X, Zhang J, He X, Gu Y, Qian BZ, Xie R, Yu W, Zhang X, Li T, Shi X*, Zhou Y*, Cui Y*. SPP1 Promotes Enzalutamide Resistance and
Epithelial-Mesenchymal-Transition Activation in Castration-Resistant Prostate Cancer via PI3K/AKT and ERK1/2 Pathways.
Oxid Med Cell Longev. 2021, 2021:5806602. IF:6.543.
15.Zhang Z, Zhang H, Li C, Xiang Q, Xu L, Liu Q, Pang X, Zhang W, Zhang H, Zhang S, Duan X, Liu Y, Cui Y*. Circulating microRNAs
as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer[J]. Thorac Cancer. 2021, 12(24):3396-3406.
IF: 3.500.
|
